Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-008 pembrolizumab plus lenvatinib versus docetaxel in previously treated metastatic NSCLC
2018-003791-12Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Feb 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + lenvatinib with Docetaxel (2 arms). Primary endpoint: Overall Survival. Started Feb 2019; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2018-003791-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003791-12.